TAAR1 and schizophrenia: These results show that the combined use of TAAR1 agonists and atypical antipsychotic drugs not only promotes the executive ability of rodents but also implies the potential benefits of reducing cognitive impairment in schizophrenia, which may provide a new idea for the treatment of cognitive impairments in schizophrenia in the future.